Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped After recruitment of Cohorts 1-4 was completed, Sponsor decided to terminate study, initially due to COVID and then considering that PK data from the dose planned to be tested in Cohort 5 (18000 mg) would be available from the ongoing Phase 3 study.

Conditions

Healthy

Interventions

DRUG: Bentracimab (PB2452) 100 mg or Placebo
DRUG: Bentracimab (PB2452) 300 mg or Placebo
DRUG: Bentracimab (PB2452) 1000 mg or Placebo
DRUG: Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment)
DRUG: Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment)
DRUG: Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment)
DRUG: Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)

Sponsor

SFJ Pharmaceuticals, Inc.